Trial reportClinical chemistry2008
Excretion of methamphetamine and amphetamine in human sweat following controlled oral methamphetamine administration.
Trial report in Clinical chemistry, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05971043 (Skin Disorders in Patients Using Methamphetamine), which is not on this map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Skin Disorders in Patients Using Methamphetamine
Who cites it
12 citing papers in PubMed, 49 citations in OpenAlex.
- Disposition of MDMA and metabolites in human sweat following controlled MDMA administration.Clinical chemistry · 2009Trial
- Alternative matrices in forensic toxicology: a critical review.Forensic toxicology · 2022Review
- The state of clinical outcome assessments for cannabis use disorder clinical trials: A review and research agenda.Drug and alcohol dependence · 2020Review
- Detection and mapping of illicit drugs and their metabolites in fingermarks by MALDI MS and compatibility with forensic techniques.Scientific reports · 2015Article
- Impact of methamphetamine on infection and immunity.Frontiers in neuroscience · 2014Review
- Biomonitoring and Elimination of Perfluorinated Compounds and Polychlorinated Biphenyls through Perspiration: Blood, Urine, and Sweat Study.ISRN toxicology · 2013Article
- Ethyl glucuronide concentrations in beard hair after a single alcohol dose: evidence for incorporation in hair root.International journal of legal medicine · 2012Article
- Incorporation of methamphetamine and amphetamine in human hair following controlled oral methamphetamine administration.Analytica chimica acta · 2012Article
- Excretion of methadone in sweat of pregnant women throughout gestation after controlled methadone administration.Therapeutic drug monitoring · 2010Article
- Monitoring pregnant women's illicit opiate and cocaine use with sweat testing.Therapeutic drug monitoring · 2010Article
- Development and validation of a solid-phase extraction gas chromatography-mass spectrometry method for the simultaneous quantification of methadone, heroin, cocaine and metabolites in sweat.Analytical and bioanalytical chemistry · 2008Article
- The afterlife of drugs and the role of pharmEcovigilance.Drug safety · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundUnderstanding methamphetamine (MAMP) and amphetamine (AMP) excretion in sweat is important for interpreting sweat and hair testing results in judicial, workplace, and drug treatment settings.
methodsParticipants (n = 8) received 4 10-mg (low) oral doses of sustained-release S-(+)-MAMP HCl (d-MAMP HCl) within 1 week in a double-blind, institutional review board-approved study. Five participants also received 4 20-mg (high) doses 3 weeks later. PharmChek sweat patches (n = 682) were worn for periods of 2 h to 1 week during and up to 3 weeks after dosing. The mass of MAMP and AMP in each patch was measured by GC-MS, with a limit of quantification of 2.5 ng/patch.
resultsMAMP was measurable in sweat within 2 h of dosing. After low and high doses, 92.9% and 62.5% of weekly sweat patches were positive, with a median (range) MAMP of 63.0 (16.8-175) and 307 (199-607) ng MAMP/patch, respectively; AMP values were 15.5 (6.5-40.5) and 53.8 (34.0-83.4) ng AMP/patch. Patches applied 2 weeks after the drug administration week had no measurable MAMP following the low doses, and only 1 positive result following the high doses. Using criteria proposed by the Substance Abuse Mental Health Services Administration, 85.7% (low) and 62.5% (high) weekly sweat patches from the dosing week were positive for MAMP, and all patches applied after the dosing week were negative.
conclusionsThese data characterize the excretion of MAMP and AMP after controlled MAMP administration and provide a framework for interpretation of MAMP sweat test results in clinical and forensic settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.